Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555408/
https://www.ncbi.nlm.nih.gov/pubmed/32957119
http://dx.doi.org/10.1182/blood.2020008394
_version_ 1784591972603789312
collection PubMed
description
format Online
Article
Text
id pubmed-8555408
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-85554082021-11-02 Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368. Blood Erratum American Society of Hematology 2020-09-10 /pmc/articles/PMC8555408/ /pubmed/32957119 http://dx.doi.org/10.1182/blood.2020008394 Text en © 2020 by The American Society of Hematology This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Erratum
Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.
title Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.
title_full Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.
title_fullStr Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.
title_full_unstemmed Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.
title_short Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.
title_sort curran kj, margossian sp, kernan na, et al. toxicity and response after cd19-specific car t-cell therapy in pediatric/young adult relapsed/refractory b-all. blood. 2019;134(26):2361-2368.
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555408/
https://www.ncbi.nlm.nih.gov/pubmed/32957119
http://dx.doi.org/10.1182/blood.2020008394

Ejemplares similares